Agarwal Pharchem India Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 26-06-2024
- Paid Up Capital ₹ 0.80 M
as on 26-06-2024
- Company Age 23 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 9.50 M
as on 26-06-2024
- Revenue %
(FY 2020)
- Profit -142.89%
(FY 2020)
- Ebitda -158.05%
(FY 2020)
- Net Worth -6.54%
(FY 2020)
- Total Assets -0.01%
(FY 2020)
About Agarwal Pharchem India
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.80 M.
The company has closed loans amounting to ₹9.50 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Mamta Agarwal and Sanjay Agarwal serve as directors at the Company.
- CIN/LLPIN
U24230MH2001PTC133827
- Company No.
133827
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Nov 2001
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Agarwal Pharchem India?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjay Agarwal  | Managing Director | 01-Nov-2001 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Mamta Agarwal | Director | 01-Nov-2001 | Current |
Financial Performance of Agarwal Pharchem India.
Agarwal Pharchem India Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 142.89% decrease in profit. The company's net worth dipped by a decrease of 6.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Agarwal Pharchem India?
In 2018, Agarwal Pharchem India had a promoter holding of 62.12% and a public holding of 37.88%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Meha Pharma Private LimitedActive 1 year 8 monthsMamta Agarwal and Sanjay Agarwal are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Saraswat Cooperative Bank Ltd Creation Date: 09 Mar 2010 | ₹4.00 M | Satisfied |
The Saraswat Co-Op Bank Ltd Creation Date: 11 Jul 2005 | ₹5.50 M | Satisfied |
How Many Employees Work at Agarwal Pharchem India?
Unlock and access historical data on people associated with Agarwal Pharchem India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Agarwal Pharchem India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Agarwal Pharchem India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
